抄録
Activation of fibrinolysis in patients with diabetic nephropathy was determined by the plasma levels of α2 plasmin inhibitor-plasmin complexes (α2 PIPC). The levels of α2 PIPC in plasma were measured by the one-step sandwich enzyme immunoassay (EIA). This quantitative assay of α2 PIPC could be valuable for the assessment of fibrinolysis. Plasma levels of α2 PIPC in diabetic patients with overt proteinuria were significantly higher than those in diabetic patients without proteinuria or in chronic glomerulonephritis patients with proteinuria (P<0.01, respectively). Plasma levels of α2 PIPC in diabetic patients with intermittent proteinuria were also significantly higher than those in diabetic patients without proteinuria or in chronic glomerulonephritis patients with proteinuria (P<0.05, respectively). These findings indicated that the activation of fibrinolysis as well as the coagulation system might play a role in the development and/or progression of diabetic nephropathy.
